450 related articles for article (PubMed ID: 17363486)
1. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of anti-tumor properties of P276-00 in head and neck squamous cell carcinoma.
Mishra PB; Lobo AS; Joshi KS; Rathos MJ; Kumar GA; Padigaru M
J Transl Med; 2013 Feb; 11():42. PubMed ID: 23414419
[TBL] [Abstract][Full Text] [Related]
4. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models.
Joshi KS; Rathos MJ; Mahajan P; Wagh V; Shenoy S; Bhatia D; Chile S; Sivakumar M; Maier A; Fiebig HH; Sharma S
Mol Cancer Ther; 2007 Mar; 6(3):926-34. PubMed ID: 17363487
[TBL] [Abstract][Full Text] [Related]
5. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
Shirsath NP; Manohar SM; Joshi KS
Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
[TBL] [Abstract][Full Text] [Related]
6. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
7. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
[TBL] [Abstract][Full Text] [Related]
9. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide.
Panigone S; Debernardi S; Taya Y; Fontanella E; Airoldi R; Delia D
Oncogene; 2000 Aug; 19(35):4035-41. PubMed ID: 10962560
[TBL] [Abstract][Full Text] [Related]
10. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
11. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel inhibitors of cyclin-dependent kinases.
Kent LL; Hull-Campbell NE; Lau T; Wu JC; Thompson SA; Nori M
Biochem Biophys Res Commun; 1999 Jul; 260(3):768-74. PubMed ID: 10403840
[TBL] [Abstract][Full Text] [Related]
13. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.
Yu B; Lane ME; Pestell RG; Albanese C; Wadler S
Mol Cell Biol Res Commun; 2000 Jun; 3(6):352-9. PubMed ID: 11032757
[TBL] [Abstract][Full Text] [Related]
15. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
16. The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.
Saleh AM; Aljada A; El-Abadelah MM; Taha MO; Sabri SS; Zahra JA; Aziz MA
Cell Physiol Biochem; 2015; 35(5):1943-57. PubMed ID: 25870953
[TBL] [Abstract][Full Text] [Related]
17. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA
J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy.
Zhang C; Lundgren K; Yan Z; Arango ME; Price S; Huber A; Higgins J; Troche G; Skaptason J; Koudriakova T; Nonomiya J; Yang M; O'Connor P; Bender S; Los G; Lewis C; Jessen B
Mol Cancer Ther; 2008 Apr; 7(4):818-28. PubMed ID: 18413795
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]